An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen
There are already two drugs on the market targeting KRAS mutations, for decades considered an undruggable target, but no shortage of drug candidates hoping to follow them.
Sleep disturbances are one of the most common and disruptive symptoms in menopausal women, but not enough is known about the causes, and current sleep aids are often ineff
New data from a phase 2b trial of Moderna and MSD’s neoantigen melanoma vaccine may be strong enough to consider filing for accelerated approval before a phase 3 programme
GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myel
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.